Dailymed elahere
WebHHMI’s Janelia Research Campus in Ashburn, Virginia, cracks open scientific fields by breaking through technical and intellectual barriers. Our integrated teams of lab scientists … WebConnect with an ELAHERE Support Services Program specialist. Phone: 1-833-ELAHERE. ( 1-833-352-4373 ) Monday to Friday, 8:00 am to 8:00 pm ET. Email: [email protected]. BACK TO TOP. …
Dailymed elahere
Did you know?
WebThe drug labels and other drug-specific information on this Web site represent the most recent drug listing information companies have submitted to the Food and Drug Administration (FDA). (See 21 CFR part 207.) The drug labeling and other information has been reformatted to make it easier to read but its content has neither been altered nor ... WebNov 20, 2024 · Elahere is a first-in-class antibody-drug conjugate directed against FRα, a cell-surface protein highly expressed in ovarian cancer. The antibody is a chimeric IgG1 directed against FRα. The small molecule, DM4, is a microtubule inhibitor designed to kill the targeted cancer cells. It is attached to the antibody via a cleavable linker.
WebDec 2, 2024 · Elahere can cause serious side effects, including: Eye problems. Eye problems are common with Elahere and can also be severe. Tell your healthcare provider right away if you develop any eye problems during treatment with Elahere, including blurred vision, dry eyes, sensitivity to light, eye pain, or new or worsening vision changes. WebNov 17, 2024 · About: Mirvetuximab soravtansine-gynx (Elahere™) Mirvetuximab soravtansine-gynx is a type of monoclonal antibody. It is a medicine designed to target a specific protein or cell – in this case, the target is a folate receptor alpha. This medication is also a microtubule inhibitor conjugate.
WebELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer … WebNov 16, 2024 · ELAHERE demonstrated an ORR by investigator of 31.7%, including five complete responses (CRs) The median DOR by investigator was 6.9 months. The drug’s safety has been evaluated from a pooled ...
WebNov 15, 2024 · Among 106 patients, the objective response rate on Elahere by investigator assessment was 31.7 percent, including five complete responses. The median duration of response was 6.9 months. ImmunoGen used Roche's assay to select patients who received treatment in the trial. Full approval of Elahere is contingent upon a confirmatory trial.
WebELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who: have not responded to or are no longer responding to treatment with platinum-based chemotherapy and. have received 1 to 3 prior types of chemotherapy. pdf not converted yetWebNov 14, 2024 · On November 14, 2024, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) … pdf not compressingWebNov 15, 2024 · ImmunoGen IMGN announced that the FDA granted accelerated approval for Elahere (mirvetuximab soravtansine-gynx) to treat adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.. Elahere is … pdf not chromeWebELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum … pdf not convertingWebMedscape - Ovarian cancer dosing for Elahere (mirvetuximab soravtansine), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & … pdf not converting to wordWebElahere (mirvetuximab sorvtansine-gynx) Requests for Elahere (mirvetuximab sorvtansine-gynx) may be approved if the following criteria are met: I. Individual has a diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer; pdf not converting to excelWebNov 15, 2024 · Most patients will receive three to four vials of Elahere per treatment cycle, putting the cost at about $18,500 to $25,000 a cycle, Immunogen Chief Executive Mark Enyedy said on a conference call. pdf not decoded correctly